CD44 inactivation in fibroblasts shrinks pancreatic tumors in mouse models via microenvironment reprogramming

Researchers at KIT and collaborators inactivated CD44 in both mouse models and human cells, observing that fibroblasts lost their activated state, produced less scar-like matrix, and allowed greater immune cell infiltration. Tumor size decreased significantly without directly killing the fibroblasts. This builds on prior KIT work targeting CD44v6 variants on cancer cells themselves with a peptide now in early clinical testing. The approach differs from stromal depletion strategies that have often worsened outcomes in pancreatic ductal adenocarcinoma trials.

Contextually, pancreatic cancer's stroma comprises up to 90% of tumor mass and drives therapy resistance, including to checkpoint inhibitors. The CD44 mechanism links fibroblast activation to both fibrotic and immune-suppressive functions, offering a dual-target opportunity. Related observational data from large PDAC cohorts show high CD44 expression correlates with poorer survival, though causation requires interventional confirmation.

Next steps include developing fibroblast-specific CD44 inhibitors and testing combinations with existing chemotherapies or immunotherapies in orthotopic models. Human safety data from the ongoing CD44v6 peptide trial will inform dosing, but off-target effects on normal fibroblasts remain uncharacterized.